Clinical Trials Directory

Trials / Unknown

UnknownNCT04324255

Von Willebrand Factor and Protein C Ratio in Graft Function After Liver Transplant

Von Willebrand Factor and Protein c Ratio-related Thrombogenicity With Systemic Inflammation is Predictive of Graft Dysfunction After Liver Transplantation: Retrospective Cohort Study

Status
Unknown
Phase
Study type
Observational
Enrollment
1,199 (estimated)
Sponsor
Asan Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

In liver cirrhosis (LC),the activity of von Willebrand factor (vWF)-cleaving enzyme ADAMTS13 is reduced in LC patients and consequent progression of liver injury. Remarkably, it has been reported that a severe vWF/ADAMTS13 imbalance develops during liver transplantation (LT) and persists even after LT. Such changes are thought to contribute to postoperative thrombotic complications, which may lead to early adverse events of thrombotic microangiopathy after living-donor LT (LDLT). We investigated whether vWFPCR could predict EAD or graft failure following LT and compared it with FVIIIPCR, procoagulant, such as vWF and FVIII and anticoagulant, such as PC.

Conditions

Interventions

TypeNameDescription
PROCEDURELTLiver transplantation

Timeline

Start date
2014-01-01
Primary completion
2016-12-30
Completion
2020-04-30
First posted
2020-03-27
Last updated
2020-03-27

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT04324255. Inclusion in this directory is not an endorsement.